And herein lies a very broad and «mushy middle,» says McKenna, with the effect, in many cases, being the same: «It's still using smaller - than - treatment doses, or sub-therapeutic doses of antibiotics,» which creates a literal breeding ground for
resistant microbial strains.
A team led by Jose García - Bustos of GlaxoSmithKline's molecular microbiology division in Tres Cantos, Spain, published the annotated but incomplete genome of a virulent, antibiotic -
resistant S. pneumoniae
strain in the June issue of
Microbial Drug Resistance.